Sanofi researching coronavirus vaccine with BARDA, using SARS vaccine - Business Insider

simply click here to claim your deal and get access to all exclusive Business Insider PRIME content.The French pharma giant plans to use its prior research from the 2002-2003 SARS outbreak to speed up the development of a coronavirus vaccine.

The French pharma giant has begun researching a vaccine to counteract the ongoing coronavirus outbreak and believes it has a head start on speedy development. Sanofi is building off of prior vaccine research on the 2002-2003 outbreak of severe acute respiratory syndrome, or SARS. The company plans to test that vaccine candidate against the virus that causes the disease known as COVID-19.

. Some are developing vaccines from scratch using info about the virus's genetic code. Others are testing existing drugs as near-term treatment options. The French pharma giant also anticipates speedy development because there is already an approved flu vaccine that uses the same manufacturing platform. Sanofi's Loew said this large-scale manufacturing is a key advantage for Sanofi in being able to quickly ramp up production of doses in a short time.

Medicine already developed. Contact-

Business Business Latest News, Business Business Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Coronavirus could impact 5 million companies worldwide, new research showsThe new coronavirus outbreak and subsequent shutdown of huge swathes of China could impact more than 5 million businesses worldwide, according to a new study. Taking the “ work from home” concept to a whole new level who cares as long as the fed printing press is on Hopefully it is becoming obvious that cruise ships aren't the best places to hold people on, to stop the spread of Coronavirus because it seems like they are helping spread it around to even more people, maybe the Ventilation system isn't the best or hasn't been cleaned properly?
Source: CNBC - 🏆 12. / 72 Read more »